CN101252928B - 作为抗菌剂的喹啉衍生物 - Google Patents

作为抗菌剂的喹啉衍生物 Download PDF

Info

Publication number
CN101252928B
CN101252928B CN2006800313527A CN200680031352A CN101252928B CN 101252928 B CN101252928 B CN 101252928B CN 2006800313527 A CN2006800313527 A CN 2006800313527A CN 200680031352 A CN200680031352 A CN 200680031352A CN 101252928 B CN101252928 B CN 101252928B
Authority
CN
China
Prior art keywords
alkyl
chemical compound
alkoxy
hydrogen
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800313527A
Other languages
English (en)
Chinese (zh)
Other versions
CN101252928A (zh
Inventor
K·J·L·M·安德里斯
A·考尔
J·E·G·吉勒蒙特
M·M·S·莫特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN101252928A publication Critical patent/CN101252928A/zh
Application granted granted Critical
Publication of CN101252928B publication Critical patent/CN101252928B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2006800313527A 2005-06-28 2006-06-26 作为抗菌剂的喹啉衍生物 Expired - Fee Related CN101252928B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05105769.3 2005-06-28
EP05105769 2005-06-28
PCT/EP2006/063556 WO2007000436A1 (en) 2005-06-28 2006-06-26 Quinoline derivatives as antibacterial agents

Publications (2)

Publication Number Publication Date
CN101252928A CN101252928A (zh) 2008-08-27
CN101252928B true CN101252928B (zh) 2012-05-23

Family

ID=35445742

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800313527A Expired - Fee Related CN101252928B (zh) 2005-06-28 2006-06-26 作为抗菌剂的喹啉衍生物

Country Status (33)

Country Link
US (2) US20100204270A1 (enExample)
EP (1) EP1898910B1 (enExample)
JP (1) JP5193859B2 (enExample)
KR (1) KR101423229B1 (enExample)
CN (1) CN101252928B (enExample)
AP (1) AP2733A (enExample)
AR (1) AR057654A1 (enExample)
AU (1) AU2006263884B2 (enExample)
BR (1) BRPI0612534B8 (enExample)
CA (1) CA2612623C (enExample)
CY (1) CY1118515T1 (enExample)
DK (1) DK1898910T3 (enExample)
EA (1) EA014163B1 (enExample)
ES (1) ES2606772T3 (enExample)
HR (1) HRP20161704T1 (enExample)
HU (1) HUE031268T2 (enExample)
IL (1) IL188394A (enExample)
JO (1) JO3270B1 (enExample)
LT (1) LT1898910T (enExample)
ME (1) ME02690B (enExample)
MX (1) MX2008000082A (enExample)
MY (1) MY151030A (enExample)
NO (1) NO341283B1 (enExample)
NZ (1) NZ564339A (enExample)
PL (1) PL1898910T3 (enExample)
PT (1) PT1898910T (enExample)
RS (1) RS55408B1 (enExample)
SG (1) SG166799A1 (enExample)
SI (1) SI1898910T1 (enExample)
TW (1) TWI392494B (enExample)
UA (1) UA91549C2 (enExample)
WO (1) WO2007000436A1 (enExample)
ZA (1) ZA200711149B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790186B2 (en) 2009-07-21 2017-10-17 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
ES2576491T3 (es) 2012-04-27 2016-07-07 Janssen Pharmaceutica, N.V. Derivados de quinolina antibacterianos
CN105037497B (zh) * 2015-03-27 2018-06-26 中牧实业股份有限公司 一种恩拉霉素的提纯方法
WO2017035288A1 (en) * 2015-08-27 2017-03-02 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
MXPA06013888A (es) * 2004-05-28 2007-01-26 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos.
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
koen andries et al.a diarylquinoline drug active on the atp synthase ofmycobacterium tuberculosis.science307.2005,307223-227. *

Also Published As

Publication number Publication date
ES2606772T3 (es) 2017-03-27
PT1898910T (pt) 2016-11-16
NO20080481L (no) 2008-02-29
UA91549C2 (ru) 2010-08-10
JO3270B1 (ar) 2018-09-16
RS55408B1 (sr) 2017-04-28
HK1120734A1 (en) 2009-04-09
IL188394A (en) 2012-09-24
US20100204270A1 (en) 2010-08-12
AR057654A1 (es) 2007-12-12
EA200800152A1 (ru) 2008-06-30
DK1898910T3 (en) 2017-01-09
NO341283B1 (no) 2017-10-02
CA2612623A1 (en) 2007-01-04
AU2006263884B2 (en) 2013-01-10
HRP20161704T1 (hr) 2017-02-10
WO2007000436A1 (en) 2007-01-04
BRPI0612534A8 (pt) 2017-12-26
MX2008000082A (es) 2008-03-24
SG166799A1 (en) 2010-12-29
EA014163B1 (ru) 2010-10-29
BRPI0612534A2 (pt) 2010-11-23
BRPI0612534B8 (pt) 2021-05-25
US20130030017A1 (en) 2013-01-31
EP1898910B1 (en) 2016-09-28
CY1118515T1 (el) 2017-07-12
ZA200711149B (en) 2009-06-24
CA2612623C (en) 2016-09-27
HUE031268T2 (en) 2017-06-28
LT1898910T (lt) 2017-01-10
TW200738237A (en) 2007-10-16
AU2006263884A1 (en) 2007-01-04
MY151030A (en) 2014-03-31
BRPI0612534B1 (pt) 2020-04-22
JP2008546825A (ja) 2008-12-25
TWI392494B (zh) 2013-04-11
JP5193859B2 (ja) 2013-05-08
SI1898910T1 (sl) 2017-01-31
KR20080028460A (ko) 2008-03-31
PL1898910T3 (pl) 2017-03-31
CN101252928A (zh) 2008-08-27
EP1898910A1 (en) 2008-03-19
IL188394A0 (en) 2008-08-07
NZ564339A (en) 2011-02-25
AP2733A (en) 2013-09-30
ME02690B (me) 2017-10-20
KR101423229B1 (ko) 2014-07-25

Similar Documents

Publication Publication Date Title
CN101277695B (zh) 作为抗菌剂的喹啉衍生物
CN101553470A (zh) 抗菌的喹啉衍生物
CN101232884B (zh) 作为抗菌剂的喹啉衍生物
CN101547907A (zh) 抗菌的喹啉衍生物
CN101277696B (zh) 作为抗菌药物的喹啉衍生物
CN101273016B (zh) 抗菌喹啉衍生物
CN101553471A (zh) 抗菌喹啉衍生物
US20130030017A1 (en) Quinoline derivatives as antibacterial agents
CN101252927A (zh) 作为抗菌剂的喹啉衍生物
CN101541752A (zh) 抗菌的喹啉衍生物
CN101247811B (zh) 作为抗菌剂的喹啉衍生物
CN101277698A (zh) 作为抗菌剂的喹啉衍生物
KR101318181B1 (ko) 항균제로서의 퀴놀린 유도체
HK1120734B (en) Quinoline derivatives as antibacterial agents
HK1122730B (en) Quinoline derivatives as antibacterial agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1120734

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1120734

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120523

CF01 Termination of patent right due to non-payment of annual fee